Physician profile
Hellen Chiao
NPI 1154681435
$10,711.57
in general payments reported to CMS, 2019-2025
36 companies · $2,306 in 2025
The $2,306 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $73.77 · 2021: $1,147 · 2022: $1,893 · 2023: $1,925 · 2024: $2,360 · 2025: $2,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,577 · Education: $13.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,577.45 |
| Education | $13.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,857.19 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,333.33 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,217.24 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $536.87 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $385.75 | 2021-2023 | Zeposia |
| Genzyme Corporation | $371.75 | 2022-2025 | |
| Pfizer INC. | $315.70 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $299.44 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $295.41 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $252.63 | 2019-2024 | Dificid, Pifeltro |
| Madrigal Pharmaceuticals | $252.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $251.33 | 2024-2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $165.76 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $140.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $130.34 | 2024 | Andexxa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $127.13 | 2024 | Barostim Neo System |
| Mauna Kea Technologies, INC. | $110.17 | 2023 | |
| Amgen INC. | $89.88 | 2021 | |
| Qol Medical, LLC | $87.82 | 2019-2022 | |
| Braintree Laboratories, INC. | $74.98 | 2019-2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $64.86 | 2024 | Voquezna |
| Shionogi INC | $43.91 | 2019 | |
| Enterra Medical, INC. | $36.89 | 2023 | |
| Redhill Biopharma INC. | $32.67 | 2020-2021 | |
| Cook Medical LLC | $31.10 | 2019-2022 | |
| Ardelyx, INC. | $25.22 | 2023 | Ibsrela |
| Alfasigma USA, INC. | $22.40 | 2020 | |
| Intra-Sana Laboratories | $21.02 | 2021 | |
| Ferring Pharmaceuticals INC. | $20.03 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.73 | 2025 | Iqirvo |
| Novo Nordisk INC | $19.11 | 2025 | Wegovy |
| Pinnacle Biologics, INC | $18.82 | 2021 | |
| Vivus LLC | $17.10 | 2024 | Qsymia |
| Alnylam Pharmaceuticals INC. | $17.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hellen Chiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.